A questionnaire-based survey investigating the current use of tranexamic acid in traumatic haemorrhage and elective hip and knee arthroplasty

Ben Young and Parvez Moondi
Queen Elizabeth Hospital, Gayton Road, King’s Lynn, Norfolk PE30 4ET, UK
Corresponding author: Ben Young. Email: benyoung101@doctors.org.uk

Abstract
Objectives: To record the current use of tranexamic acid during traumatic haemorrhage and elective arthroplasty of the hip and knee.
Design: A questionnaire-based postal survey.
Setting: The questionnaire was sent to the ‘anaesthetic lead’ at all acute trusts in England, excluding centres for children, women’s health, cancer and cardiac care.
Participants: Ninety-nine (66%) centres replied to the questionnaire.
Main outcome measures: Is tranexamic acid used as part of routine standardized treatment for traumatic haemorrhage and for elective hip and knee arthroplasty, and if so what dosage regime was administered?
Results: Few trusts (31%) use tranexamic acid during traumatic haemorrhage, with various dosages used. Its use in hip and knee arthroplasty was also low (38%) with a diverse range of doses prescribed.
Conclusions: Despite many trials showing its efficacy and low risk of side effect, it is clear that its use is not part of standard practice in most centres. Further studies could clarify these concerns and provide a definitive dosing schedule improving patient care and saving lives.

Keywords
tranexamic acid, arthroplasty, traumatic haemorrhage, enhanced recovery

Introduction
Tranexamic acid has been used for many decades to reduce bleeding. It is an inexpensive, easily used, and relatively safe drug. In 1970, the British Medical Journal published results of a trial showing that the use of tranexamic acid significantly decreased menstrual blood loss in women with menorrhagia. Since then its use has spread throughout the surgical specialties including orthopaedic surgery. In traumatic haemorrhage, its use was investigated by the CRASH-2 trial, which concluded that it could reduce blood loss and may prevent thousands of premature trauma deaths each year. In recent years, several systematic reviews and meta-analyses have evaluated the effect of tranexamic acid upon blood loss and transfusion rates in primary total knee and hip replacements. They demonstrated a statistically significant reduction in total blood loss and blood transfusion requirements. A literature review of tranexamic acid in orthopaedic arthroplasty of the hip and knee found many small trials investigating its use.

In these limited studies, there was a wide range of different dosing regimens used, involving patient groups of not more than 100. An online search revealed several enhanced recovery programmes running in orthopaedic departments around the country, advocating the use of tranexamic acid in primary orthopaedic arthroplasty of the hip and knee. Again, these all used different dosage regimens.

The aim of this study was to record the use of tranexamic acid in England during traumatic haemorrhage and elective hip and knee arthroplasty.

Methods
A postal questionnaire was sent to the anaesthetic lead of all acute English trusts, excluding centres for children, women’s health, cancer and cardiac care. The questionnaire asked whether tranexamic acid was used as part of their routine standardized treatment for traumatic haemorrhage and for elective hip and knee arthroplasty, and if so what dosage regime was administered.

Results
One hundred forty-nine acute trusts were identified as suitable with 99 responding (66%). Ninety-five per cent of responders had service provision for trauma, and of these centres 31% routinely used tranexamic acid in cases of traumatic haemorrhage. Of those that routinely used tranexamic acid only 21% followed
the regimen used in the CRASH-2 trial – 1 g followed by infusion of 1 g over 8 h. The other doses that were given are shown in Table 1.

Of the responders 99% performed routine arthroplasty work, with 38% using tranexamic acid as part of their routine standard practice. The most common dose given was 1 g, being used 54% of the time. Postoperative doses were given by 11%. The other doses that were given are shown in Table 2.

**Discussion**

It can be seen from this survey that 69% of trusts that responded do not routinely use tranexamic acid during cases of traumatic haemorrhage. Our results for elective hip and knee arthroplasty show 62% of trusts that responded do not routinely use tranexamic acid. Our survey shows the most common dose given is one dose of 1 g without any postoperative doses, however, a variety of different dosage regimens was observed.

Although the questionnaire was addressed to the ‘anaesthetic lead’ of each acute trust’s anaesthetic department, the results may be an underestimate due to its selective use by certain surgeons and anaesthetists. Also, given selectivity bias of a questionnaire, the results may not accurately reflect the precise usage. Nonetheless, it is clear that tranexamic acid is not part of standard practice in most centres.

The CRASH-2 trial established tranexamic acid as an effective hospital-based treatment for traumatic haemorrhage. However, since its publication many questions have been raised; in particular the timing of tranexamic acid, its possible harm if administered late, and its use in a society such as ours where massive transfusion protocols incorporate treatment such as fresh-frozen plasma. Despite this, analysis of the CRASH-2 trial has concluded that tranexamic acid does have a beneficial role if administered within 3 h of injury.\(^{15}\) This survey also highlighted just how varied the dosage regimens are, even after the large multicentre multinational CRASH-2 trial. Multiple small trials have shown benefit in reducing blood loss for elective hip and knee arthroplasty.\(^{7-11}\) Various dosage regimes were used and the optimum dose is unclear. The need for postoperative doses is also unclear.

The low compliance observed with the use of tranexamic acid is likely multifactorial. As well as the uncertainty of the optimum dose and its timing, the low compliance may be due to concerns regarding complications, especially thromboembolism. Numerous studies have analysed the thromboembolic risk and concluded that it is negligible or low.\(^{8,9,11,16,17}\)

Despite many trials showing its efficacy and low risk of side effect, it is clear that its use is not part of standard practice in most centres. A further large randomized multicentre trial could clarify these concerns and provide a definitive dosing schedule and potentially confirm tranexamic acid’s place in protocolized management of arthroplasty and bleeding trauma patients, improving patient care and saving lives.

| Dose                                             | Total number (%) |
|--------------------------------------------------|------------------|
| CRASH-2 trial dose (1 g followed by infusion of 1 g over 8 h) | 21               |
| Two doses of 1 g, with the second dose after 8 h    | 21               |
| Single 1 g dose                                   | 34               |
| Single 10 mg/kg dose                              | 7                |
| Other doses                                       | 17               |

**Table 2.** The differing doses prescribed by acute trusts that routinely used tranexamic acid during elective hip and knee arthroplasty.

| Dose               | Total number (%) |
|--------------------|------------------|
| Single 1 g dose    | 54               |
| Two doses of 1 g, with the second dose after 8 h | 8 |
| Three doses of 1 g, with the subsequent doses 8 h | 3 |
| Single 15 mg/kg dose | 11          |
| Single 10 mg/kg dose | 11            |
| Single 20 mg/kg dose | 5             |
| Single 2 g dose    | 8                |
Declarations

Competing interests: None declared

Funding: None declared

Ethical approval: Ethical approval was not required for this study as it was an evaluation of current practice that did not involve access to or collection of private, sensitive or health data.

Guarantor: PM

Contributorship: Parvez Moondi (Consultant Anaesthetist, Queen Elizabeth Hospital Kings Lynn) conceived the study. Ben Young designed the questionnaire, performed the analysis and wrote the manuscript.

Acknowledgements: The authors would like to thank all the trusts that responded to the questionnaire, and to Alicia Griffiths who helped distribute and collect the survey.

Provenance: Not commissioned; editorial review.

References

1. Callender Shei La T, Warner GT and Cope E. Treatment of menorrhagia with tranexamic acid. Br Med J 1970; 4: 214–216.

2. The CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096–1101.

3. Sukeik M, Alshryda S, Haddad FS and Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg 2011; 93: 39–46.

4. Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J and Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg 2011; 93: 1577–1585.

5. Yang ZG, Chen WP and Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg 2012; 94: 1153–1159.

6. Zhou XD, Tao LJ and Li J. Do we really need tranexamic acid in total hip arthroplasty? A meta-analysis of nineteen randomized controlled trials. Arch Orthop Trauma Surg 2013; 133: 1017–1027.

7. Hynes MC, Calder P, Rosenfeld P and Scott G. The use of tranexamic acid to reduce blood loss during total hip arthroplasty: an observational study. Ann R Coll Surg Engl 2005; 87: 99–101.

8. Orpen NM, Little C, Walker G and Crawfurd EJ. Tranexamic acid reduces early post-operative blood loss after total knee arthroplasty: a prospective randomised controlled trial of 29 patients. Knee 2006; 13: 106–110.

9. Rajesparan K, Bianl LC, Ahmad M and Field RE. The effect of an intravenous bolus of tranexamic acid on blood loss in total hip replacement. J Bone Joint Surg 2009; 91: 776–783.

10. McConnell JS, Shewale S, Munro NA, Shah K, Deakin AH and Kinninmonth AW. Reduction of blood loss in primary hip arthroplasty with tranexamic acid or fibrin spray. Acta Orthop 2011; 82: 660–663.

11. Hynes M, Calder P and Scott G. The use of tranexamic acid to reduce blood loss during total knee arthroplasty. Knee 2003; 10: 375–377.

12. Trust Guideline for the Enhanced Recovery Programme for Total Hip and Total Knee Replacement at the Norfolk and Norwich University Hospital 2010, http://www.ukcpa.net/wp-content/uploads/group-documents/30/1317819839-CA4091_EnhancedRecoveryProgrammeforTotalHipandTotalKneeReplacement.doc (2010, accessed 22 October 2013).

13. Protocol for Enhanced Recovery Orthopaedic Hip and Knee Joint Replacement Patients at Hull and East Yorkshire Hospitals 2012, http://frcaheadstart.org/ortho_ERAS_CHH.pdf (2012, accessed 22 October 2013).

14. Enhanced Recovery Protocol for Elective Hip and Knee Replacements at Doncaster and Bassetlaw Hospitals, http://dbh.nhs.uk/Library/Pharmacy_Medicines_Management/Formulary/Formulary_S4/Enhanced%20Recovery%20Protocol%20Orthopaedics.pdf (last, accessed 22 October 2013).

15. CRASH-2 Trial Collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096–1101.

16. Blake PG, Lori JD, Robert TT, Mark WP and Sierra RJ. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty. Clin Orthop Relat Res 2013; 471: 150–154.

17. Lozano M, Basora M, Peidro L, Merino I, Segur JM, Pereira A, Salazar F, Cid J, Lozano L, Mazzara R and Macule F. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. Int J Transfus Med 2008; 95: 39–44.